secwatch.observer — SEC 8-K summary
======================================

Issuer:     Regen BioPharma Inc (RGBP)
CIK:        0001589150
Form:       8-K
Filed at:   2021-08-26T23:59:59+00:00
Accession:  0001607062-21-000297
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Regen Biopharma receives U.S. patent for mRNA-based cancer vaccine technology
-----------------------------------------------------------------------------

- USPTO issued Patent No. 11,090,332 B2 on August 17, 2021, for "Antigen Specific MRNA Cellular Cancer Vaccines".
- The invention covers modified mRNA encoding immunogenic epitopes, e.g., survivin-derived peptides, to induce intracellular antigen production.
- Patent aims to expand epitope repertoire presented to adaptive immune system, improving likelihood of successful immunity induction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1589150/000160706221000297/0001607062-21-000297-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1589150/000160706221000297/rgbp082621form8k.htm
  HTML page:      https://secwatch.observer/filing/0001607062-21-000297

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer